These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
549 related articles for article (PubMed ID: 11406568)
1. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568 [TBL] [Abstract][Full Text] [Related]
2. HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis. Dubská L; Andera L; Sheard MA FEBS Lett; 2005 Aug; 579(19):4149-58. PubMed ID: 16023111 [TBL] [Abstract][Full Text] [Related]
3. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935 [TBL] [Abstract][Full Text] [Related]
4. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R; Bedi A Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014 [TBL] [Abstract][Full Text] [Related]
5. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Cuello M; Ettenberg SA; Nau MM; Lipkowitz S Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126 [TBL] [Abstract][Full Text] [Related]
6. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352 [TBL] [Abstract][Full Text] [Related]
7. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528 [TBL] [Abstract][Full Text] [Related]
8. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M Cancer Res; 2003 Mar; 63(6):1365-70. PubMed ID: 12649200 [TBL] [Abstract][Full Text] [Related]
9. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823 [TBL] [Abstract][Full Text] [Related]
10. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300 [TBL] [Abstract][Full Text] [Related]
12. eNOS protects prostate cancer cells from TRAIL-induced apoptosis. Tong X; Li H Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122 [TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Gibson EM; Henson ES; Haney N; Villanueva J; Gibson SB Cancer Res; 2002 Jan; 62(2):488-96. PubMed ID: 11809700 [TBL] [Abstract][Full Text] [Related]
14. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase. Cenni V; Maraldi NM; Ruggeri A; Secchiero P; Del Coco R; De Pol A; Cocco L; Marmiroli S Int J Oncol; 2004 Dec; 25(6):1599-608. PubMed ID: 15547696 [TBL] [Abstract][Full Text] [Related]
15. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Singh TR; Shankar S; Chen X; Asim M; Srivastava RK Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373 [TBL] [Abstract][Full Text] [Related]
17. Amiloride potentiates TRAIL-induced tumor cell apoptosis by intracellular acidification-dependent Akt inactivation. Cho YL; Lee KS; Lee SJ; Namkoong S; Kim YM; Lee H; Ha KS; Han JA; Kwon YG; Kim YM Biochem Biophys Res Commun; 2005 Jan; 326(4):752-8. PubMed ID: 15607733 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225 [TBL] [Abstract][Full Text] [Related]
19. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Longva KE; Pedersen NM; Haslekås C; Stang E; Madshus IH Int J Cancer; 2005 Sep; 116(3):359-67. PubMed ID: 15800944 [TBL] [Abstract][Full Text] [Related]
20. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Oka N; Nakahara S; Takenaka Y; Fukumori T; Hogan V; Kanayama HO; Yanagawa T; Raz A Cancer Res; 2005 Sep; 65(17):7546-53. PubMed ID: 16140916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]